Top Clinical Trials and Results to Watch in Early 2026
TL;DR
The article previews ten significant clinical trials expected in the first half of 2026, focusing on Eli Lilly's obesity drug retatrutide, Merck's flu antiviral CD388, Regenxbio's gene therapy for Duchenne muscular dystrophy, Novartis' Lp(a) cardiovascular treatment, and other innovative therapies for rare diseases and cardiovascular conditions. Success in these trials could lead to major advancements and market approvals in their respective fields.
- 10 clinical trials to watch in the first half of 2026 BioPharma Dive
- 5 Clinical Readouts to Watch in H1 2026 BioSpace
- Samuel Hume: 5 Clinical Trials to Watch in 2026 Oncodaily
- Novartis and Eli Lilly to Announce Key Clinical Trial Results for Cardiovascular and Alzheimer’s Drugs in Early 2026 geneonline.com
- Biotech Industry Sees Resurgence with Ten Clinical Trials Set to Deliver Results in 2026 geneonline.com
Want the full story? Read the original reporting
Read on BioPharma Dive